Clinical trial · people

Teriparatide then denosumab: 21.9% spine bone density gain

Checked against the paper Clinical trialPublished by PepVault

The takeaway

For people using teriparatide, this study shows that following it with denosumab kept raising bone density in premenopausal women with severe osteoporosis.

Kind
Clinical trial
Studied in
People
Number studied
32
Published
2022
Journal
J Clin Endocrinol Metab

What they tested

The team wanted to see what 12 and 24 months of denosumab does to bone in premenopausal women with idiopathic osteoporosis (bone loss with no known cause) who had just finished 24 months of teriparatide.

How the study was done

A preplanned phase 2B extension study with no comparison group. Women who had completed teriparatide received the trial's denosumab schedule of 60 mg every 6 months for 24 months; 32 took it for 12 months and 29 for 24 months.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

On denosumab, bone mineral density (BMD) at the lumbar spine rose 5.2% at 12 months and 6.9% at 24 months. The total hip rose 2.9% and 4.6%, and the femoral neck rose 3.0% and 4.7%. Across the full 24 months of teriparatide plus 24 months of denosumab, BMD rose 21.9% at the lumbar spine, 9.8% at the total hip and 9.5% at the femoral neck, all statistically significant. Trabecular bone score, a score of the spongy inner bone's structure, rose 5.8%; blood markers of bone turnover fell 75% to 85% by 3 months and stayed low through 12 months, and denosumab was generally well tolerated.

What it doesn’t show

This was a small extension study with no control group, so it can't show how this sequence compares with teriparatide alone or another follow-up drug. It included only premenopausal women with severe idiopathic osteoporosis, and it measured bone density and markers rather than fracture rates.

The paper

Shane et al. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis. J Clin Endocrinol Metab. 2022.

The compound

More studies on Teriparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking teriparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo